It is a new chemical entity developed based on phage recombinant protein technology. The drug candidate acts by targeting peptidoglycan. GlobalData, the leading provider of industry intelligence, ...

P-128 is under clinical development by GangaGen Biotechnologies and currently in Phase II for Staphylococcus aureus Infections.

Department of Chemistry, Indiana University, 800 E. Kirkwood Avenue, Bloomington, Indiana 47405, United States ...

Some tissue matrices are fibrous, contained in protective cell walls, or behind tough peptidoglycan layers that are difficult to disassociate quickly and consistently, whiles others can easily be ...